Latest Hotspot

FDA Approves Galapagos' IND for Phase 1/2 Trial of GLPG5101, a CD19 CAR-T Therapy

27 August 2024
3 min read

Galapagos NV (Euronext & NASDAQ: GLPG) reported that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug (IND) application for ATALANTA-1. This Phase 1/2 multicenter trial is designed to assess the feasibility, safety, and effectiveness of GLPG5101 in patients who have relapsed or are refractory to treatment for non-Hodgkin lymphoma (R/R NHL).

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 应用程序

描述已自动生成

GLPG5101, an autologous CD19 CAR-T cell therapy candidate, is developed using Galapagos’ cutting-edge decentralized cell therapy production platform. This approach allows for the potential administration of fresh, viable cells within a median vein-to-vein timeframe of seven days.

The main goal of the Phase 1 segment of the ATALANTA-1 trial is to assess the safety and initial efficacy of GLPG5101 to establish the optimal dose for Phase 2. Additional aims include evaluating the efficacy and practicality of the decentralized production of GLPG5101. For Phase 2, the primary objective is to determine the objective response rate, while secondary objectives encompass the complete response rate, response duration, progression-free survival, overall survival, safety, pharmacokinetics, and the feasibility of decentralized manufacturing. Patients will be monitored for a duration of 24 months.

The ongoing Phase 1/2 ATALANTA-1 study in Europe has shown promising early outcomes in individuals with R/R NHL.

"We are committed to propelling innovative advancements that expand the accessibility of cell therapies for patients facing rapidly advancing cancers," stated Dr. Paul Stoffels, CEO and Chairman of the Board of Directors at Galapagos. "Our pioneering decentralized manufacturing platform is crafted to address numerous obstacles encountered by current CAR-T production technologies. This platform from Galapagos promises enhanced speed and scalability, providing fresh, viable cells within a seven-day median vein-to-vein period, directly to patients. The IND clearance for the Phase 1/2 GLPG5101 study represents a crucial advancement in our cell therapy program, progressing us towards delivering our CD19 CAR-T cell therapy to U.S. patients."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of August 27, 2024, there are 9 investigational drugs for the 4-1BB x CD19 targets, including 29 indications, 11 R&D institutions involved, with related clinical trials reaching 22, and as many as 10869 patents.

GLPG-5101 is an autologous CAR-T drug that targets 4-1BB x CD19 and is being developed by Galapagos NV. The therapeutic areas that this drug aims to treat include neoplasms, immune system diseases, hemic and lymphatic diseases, as well as skin and musculoskeletal diseases. The active indications for GLPG-5101 are Non-Hodgkin Lymphoma and Systemic Lupus Erythematosus. This drug is currently in the Phase 2 stage of development, which represents a significant advancement in its clinical testing. Phase 2 trials involve a larger group of patients and are conducted to further evaluate the drug's safety and efficacy.

图形用户界面, 文本, 应用程序

描述已自动生成

Moderna Gains European Commission Nod for RSV Vaccine mRESVIA(R)
Latest Hotspot
3 min read
Moderna Gains European Commission Nod for RSV Vaccine mRESVIA(R)
27 August 2024
Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.
Read →
Mabwell Receives CDE Nod for New Nectin-4 ADC, Set to Start Phase III Cervical Cancer Trial
Latest Hotspot
3 min read
Mabwell Receives CDE Nod for New Nectin-4 ADC, Set to Start Phase III Cervical Cancer Trial
27 August 2024
The company will commence a Phase III clinical trial aiming to investigate the effectiveness and safety of 9MW2821 in individuals with recurrent or metastatic cervical cancer (CC).
Read →
YolTech Therapeutics Initiates Clinical Trial with First Dose of YOLT-203 for In Vivo Gene Editing in PH1 Therapy
Latest Hotspot
4 min read
YolTech Therapeutics Initiates Clinical Trial with First Dose of YOLT-203 for In Vivo Gene Editing in PH1 Therapy
27 August 2024
YolTech Therapeutics Administers First Patient Dose of YOLT-203 in Clinical Trial for Groundbreaking In Vivo Gene Editing Therapy for PH1.
Read →
Accelerating mRNA Therapeutics Research: Harnessing Patsnap Bio for Efficient Nucleotide Sequence Retrieval and Patent Analysis
Bio Sequence
5 min read
Accelerating mRNA Therapeutics Research: Harnessing Patsnap Bio for Efficient Nucleotide Sequence Retrieval and Patent Analysis
27 August 2024
we will proceed with a specific sequence example to explore how nucleotide information can be efficiently retrieved using Patsnap Bio.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.